# Adlinda Alip

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/adlinda-alip/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,358 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 12 |
| i10-index | 13 |
| Last Known Institution | University of Malaya |
| OpenAlex ID | https://openalex.org/A5009388145 |
| ORCID iD | 0000-0003-4744-4533 |
| Works | 57 |

## Researcher papers

- [Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/amivantamab-plus-lazertinib-in-previously-untreated-i-egfr-i-mutated-advanced/)
- [Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-clinical-practice-guidelines-for-the-management-of-patients/)
- [Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-clinical-practice-guidelines-for-the-management-of/)
- [Overall Survival with Amivantamab–Lazertinib in <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-amivantamab-lazertinib-in-i-egfr-i-mutated-advanced-nsclc/)
- [Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA](https://scholariq.org/papers/amivantamab-plus-lazertinib-versus-osimertinib-in-first-line-egfr-mutant/)
- [LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results from MARIPOSA, a phase III, global, randomized, controlled trial](https://scholariq.org/papers/lba14-amivantamab-plus-lazertinib-vs-osimertinib-as-first-line-treatment-in/)
- [4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study](https://scholariq.org/papers/4o-amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-1l-egfr-mutant-egfrm/)
- [Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study](https://scholariq.org/papers/real-world-experience-of-first-line-afatinib-in-patients-with-egfr-mutant/)
- [Barriers of and strategies for shared decision‐making implementation in the care of metastatic breast cancer: A qualitative study among patients and healthcare professionals in an Asian country](https://scholariq.org/papers/barriers-of-and-strategies-for-shared-decision-making-implementation-in-the-care/)
- [Amivantamab plus lazertinib vs osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.](https://scholariq.org/papers/amivantamab-plus-lazertinib-vs-osimertinib-in-first-line-i-egfr-i-mutant/)
- [P1.15-15 Real-world Experience with Afatinib after Failure of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor](https://scholariq.org/papers/p1-15-15-real-world-experience-with-afatinib-after-failure-of-first-generation/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [University of Malaya](https://scholariq.org/institutions/university-of-malaya/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.